Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
European Urology Oncology|May 29, 2021
Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell CarcinomaMichael A Gorin, Hiten D Patel, Steven P Rowe, et al.
Cancer Immunology Research|October 4, 2017
Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor MicroenvironmentYuki Muroyama, Thomas R Nirschl, Christina M Kochel, et al.
Journal for Immunotherapy of Cancer|July 1, 2021
TGM4: an immunogenic prostate-restricted antigenZoila A Lopez-Bujanda, Aleksandar Obradovic, Thomas R Nirschl, et al.
Journal for Immunotherapy of Cancer|May 19, 2016
Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial gliomaMira A Patel, Jennifer E Kim, Debebe Theodros, et al.
Journal for Immunotherapy of Cancer|November 9, 2016
Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial gliomaMira A Patel, Jennifer E Kim, Debebe Theodros, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2020
T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate CancerAleksandar Z Obradovic, Matthew C Dallos, Marianna L Zahurak, et al.
The Journal of Clinical Investigation|February 5, 2020
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer targetZachary T Freeman, Thomas R Nirschl, Daniel H Hovelson, et al.
Scientific Reports|January 16, 2024
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinomaNirmish Singla, Thomas R Nirschl, Aleksandar Z Obradovic, et al.
Oncotarget|May 4, 2018
PD-L1 expression in medulloblastoma: an evaluation by subgroupAllison M Martin, Christopher J Nirschl, Magda J Polanczyk, et al.
Pageof 3